BioDiem secures Japanese patent for BDM-I


By Dylan Bushell-Embling
Friday, 24 May, 2013

BioDiem (ASX:BDM) has expanded its IP protection, securing another Japanese patent for antimicrobial compound BDM-I.

The new patent covers BDM-I as a treatment for malaria and the STD trichomoniasis - both protozoic infections.

BioDiem has already secured similar patents in Europe and the US, and also has patents across all three markets covering BDM-I’s treatment of vulvovaginitis infections caused by thrush, gonorrhoea and chlamydia.

“This latest protozoal patent, coupled with our previous vulvovaginitis patent in key markets, means we now have a comprehensive intellectual property set for the treatment of common female genital health complaints,” BioDiem CEO Julie Phillips said.

BioDiem also has BDM-I patents in Canada, China and Singapore. The company has separately licensed hepatitis B and D vaccine technology from the University of Canberra.

The company is evaluating BDM-I against a range of additional targets, including pneumocystosis, fungal infections and tuberculosis, and the parasitic worms that cause schistosomiasis.

BioDiem shares were trading 11.11% higher at $0.03 as of around 2 pm on Thursday.

Related News

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd